04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
15:19 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

CARsgen solid tumor CAR T leads to complete response

CARsgen Therapeutics Co. Ltd. (Shanghai, China) said its CAR-CLD18 T cell therapy led to five objective responses, including one complete response, in a pilot trial to treat relapsed or refractory gastric or pancreatic cancer. The...
19:45 , Sep 10, 2018 |  BC Extra  |  Clinical News

CARsgen solid tumor CAR T leads to complete response

CARsgen Therapeutics Co. Ltd. (Shanghai, China) said its CAR-CLD18 T cell therapy led to five objective responses, including one complete response, in a pilot trial to treat relapsed or refractory gastric or pancreatic cancer. The...
02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring...
20:42 , Oct 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Solid tumors Patient sample, cell culture, mouse and monkey studies suggest ERY974 , a bispecific antibody against CD3 and GPC3 , could help treat multiple types of GPC3-positive solid tumors. In tissue samples from...
22:45 , Oct 4, 2017 |  BC Extra  |  Preclinical News

Chugai team describes bispecific GPC3 antibody's efficacy

A study published Wednesday in Science Translational Medicine described a novel bispecific antibody that overcomes the "on-target, off-tumor" effects plaguing current cancer immunotherapies utilizing bispecific T-cell redirecting antibodies (TRAB). While the efficacy of current TRAB...
19:55 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

CARsgen reports Phase I data for anti-GPC3 CAR T in HCC

CARsgen Therapeutics Co. Ltd. (Shanghai, China) reported preliminary data from 5 evaluable patients with relapsed or refractory hepatocellular carcinoma (HCC) in a Chinese Phase I trial showing that CSG-GPC3 following lymphodepleting conditioning with fludarabine and...
02:14 , Jan 26, 2016 |  BC Extra  |  Financial News

Chinese CAR-T play CARsgen raises $30M

CARsgen Therapeutics Co. Ltd. (Shanghai, China) raised $30 million in a series B round led by KTB Ventures and Jolly Innovation Ventures. Kaitai Capital and JIC GenesisFountain Healthcare Ventures also participated. CARsgen is developing chimeric...
07:00 , Apr 9, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Glypican 3 (GPC3)

Cancer INDICATION: Liver cancer In vitro and mouse studies suggest a GPC3-targeting immunotoxin could help treat liver cancer. The immunotoxin consisted of a peptide fragment of a Pseudomonas exotoxin fused to an anti-GPC antibody that...
08:00 , Dec 15, 2014 |  BioCentury  |  Finance

CAR T bet in China

BVCF typically invests in later-stage healthcare plays in China, but the PE firm's Zhi Yang said BVCF went out of its comfort zone by investing in a series A round in new cancer immunotherapy play...